Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics NASDAQ:CTNM said on Monday an experimental depression drug it developed with Johnson & Johnson NYSE:JNJ failed to meet the main goal of a mid-stage study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.